CDH17 and prostate carcinoma: For example, kurarinone has been reported to have anticancer potential against cervical, lung, hepatic, esophageal, breast, gastric, cervical, and prostate cancers, potentially by inhibiting cell cycle progression, inducing apoptosis, and suppressing metastasis of cancer cells through the modulation of signal mediators such as NF-κB, caspases, and cadherins [33].